At the ongoing WORLDSymposium meeting in San Diego, Gain Therapeutics Inc. presented preclinical data on the company’s GCase enhancer GT-02287 as a potential approach to rescue motor function in Parkinson’s disease (PD).
Researchers from Texas A&M University System have detailed the development and characterization of a novel pediatric rat model of organophosphate (OP)-induced status epilepticus (SE).
It is well known that protein tau forms aggregates in the brain in neurodegenerative diseases such as Alzheimer’s disease (AD) that are also known as tauopathies. Accumulation of protein tau in the brain leads to the cell toxicity and promotes the loss of synaptic plasticity, which in turn causes memory loss. As reported on Feb. 1, 2024, in The Journal of Clinical Investigation, assistant professor Tara Tracy and her research team from the Buck Institute for Research on Aging have discovered a protein in the brain that could restore this damage induced by protein tau.
Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) caused by nerve inflammation that affects over 2 million people globally. Bromodomain and extra-terminal domain (BET) proteins, containing BD1 and BD2 bromodomains, are among the proteins dysregulated in MS.
Researchers from Lanzhou University have described the discovery and preclinical evaluation of new multifunctional opioid agonists being developed as potential antinociceptive agents.
Although several mouse models have been developed to investigate the mechanisms underlying Alzheimer’s disease (AD), most of them are transgenic and, therefore, present disadvantages in terms of costs and time constraints. To overcome these limitations and develop a more cost-effective and reliable animal model, a team of researchers from JSS Academy of Higher Education & Research and collaborators recently proposed a novel pharmacological AD model in zebrafish using aluminum chloride (AlCl3).
Igc Pharma Inc. has reported additional results of preclinical studies investigating TGR-63, a potential treatment for Alzheimer’s disease. TGR-63 is designed to disrupt the structure of the amyloid-β (Aβ) peptide, one of the key hallmarks of Alzheimer’s.
Evidence from research has pointed to a positive correlation between high glucocorticoid levels and the advancement of Huntington's disease (HD). Researchers from Leiden University Medical Center and Corcept Therapeutics Inc. have reported on the evaluation of CORT-113176 (dazucorilant), a glucocorticoid receptor antagonist, in mouse models of HD.
RSS
